

Learner Notification

MED Learning Group

Current Gaps in Therapy in Patients With Nontuberculous Mycobacterial Lung Disease (NTM-LD): Improving Adherence With Guideline-Recommended Strategies

June 9, 2023 – June 9, 2024

Online

Acknowledgement of Financial Commercial Support

Insmmed, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Summarize the science and technology behind multi-cancer early detection testing.
2. Assess the accuracy of MCED technologies and effectively communicate these results to patients.
3. Review and overcome clinician and patient barriers to implementation of MCED testing in order to better integrate these tests into primary care.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Felecia	Beachum	NA
Charles L.	Daley	AN2, AstraZeneca, Cepheid, Genentech, Hyfe, Insmmed, Paratek, Pfizer, Spero, Zambon: Consultant, AN2, Beyond Air, Bugworks, Insmmed, Juvabis, Paratek: Contracted Research, Gates Foundation, Lilly and Otsuka: Data Monitoring Committee
Naomi	De Brito	NA
Matthew	Frese	NA
Christina	Gallo	NA
Debra	Gordon	NA
Shannon	Kasperbauer	AN2 Pharmaceuticals, Insmmed, Paratek: Speakers Bureau, AN2 Pharmaceuticals, Insmmed, Paratek: Consultant
Jo	Shultz	NA

Lauren

Welch

NA

Questions? Email Certificate@AmedcoEmail.com